Figure 7. Targeting MUC1-C decreases pluripotency factor expression and tumorigenicity.

(A) Lysates from SW620 tet-CshRNA and SW620 tet-MUC1shRNA cells treated with vehicle or 500 ng/mL DOX for 7 days run in the same gel as shown for the data in Figure 6B were immunoblotted with antibodies against the indicated proteins and include the same GAPDH blots. (B) Lysates from SW620 cells left untreated or treated with 5 μM GO-203 for 48 hours were immunoblotted with antibodies against the indicated proteins. (C) Lysates from SW620 tet-MYCshRNA treated with vehicle or 500 ng/mL DOX for 7 days were immunoblotted with antibodies against the indicated proteins. (D and E) Nude 6-week-old male mice were injected subcutaneously in the flank with 3 × 10⁶ SW620 tet-MUC1shRNA cells. Mice were pair matched into 2 groups when tumors reached 100–150 mm³ and were fed without and with DOX. Tumor volumes are expressed as the mean ± SD for 6 mice (D). Lysates from tumors obtained on the indicated days were immunoblotted with antibodies against the indicated proteins (E).